GLP-1 Medications and Erectile Function

The expected relationship between GLP-1 medications and erectile function is straightforward. Obesity and type 2 diabetes damage erectile function through endothelial dysfunction, small vessel disease, and reduced testosterone. Weight loss improves it. Drugs producing 15% to 20% body weight loss should therefore improve erections substantially.

Recent data complicate that. Two studies have found more erectile dysfunction among men taking these drugs, not less. The picture is unsettled, and this article sets out what has been found rather than resolving it.

The case for benefit

Weight loss improves erectile function. Randomized trials of lifestyle change in obese men have shown improvement, and meta-analyses of weight-loss trials have reached the same conclusion.

The mechanisms are established. Excess adipose tissue increases aromatase activity, which converts testosterone to estradiol and lowers testosterone. Obesity and diabetes drive endothelial dysfunction, and the endothelium is where the nitric oxide signaling that produces an erection begins. The penile arteries are small, so they show vascular damage earlier than the coronary arteries do.

Beyond that, these drugs reduce major adverse cardiovascular events substantially in men with established cardiovascular disease, and they have real kidney benefits. Those effects are not in dispute and are considerably more important than erectile function.

What the recent studies found

Tang and colleagues published a target trial emulation in 2026, using electronic health records from a US health system between January 2019 and September 2024. Men with type 2 diabetes starting a GLP-1 receptor agonist were compared with men starting a DPP-4 inhibitor, with baseline characteristics balanced by inverse probability of treatment weighting. Starting a GLP-1 was associated with a modestly increased risk of erectile dysfunction. The association held across sensitivity analyses.

A separate cohort study using the TriNetX database (Able et al., 2025) looked at non-diabetic men with obesity prescribed semaglutide for weight loss, and reported a higher rate of erectile dysfunction and greater use of PDE5 inhibitors compared with men not taking it.

Two independent datasets pointing the same direction should be taken seriously. It is not the same as proof.

Why this might not mean what it looks like

Several explanations sit between the data and the conclusion that these drugs cause erectile dysfunction.

Detection. Men starting a GLP-1 are seen more often, weighed, and questioned. Erectile dysfunction that already existed is more likely to be recorded in a man under active management than in one who is not. Comparison against another diabetes drug reduces this problem but does not remove it, because the two groups are not followed identically.

Confounding by indication. Men prescribed a GLP-1 tend to be heavier and to have more metabolic disease than men prescribed a DPP-4 inhibitor. Statistical adjustment handles what is measured, not what is not.

Speed and composition of weight loss. Rapid loss on these drugs includes lean mass as well as fat. Whether that matters for erectile function is unknown.

Mechanism is unclear. The authors of the 2026 study describe the biological mechanism as incompletely understood. The leading hypothesis is that GLP-1 receptor agonists may alter autonomic balance, since erection depends on parasympathetic signaling, and preclinical work suggests these drugs can shift sympathetic-parasympathetic tone. That is a hypothesis rather than an established pathway. A drug that improves endothelial function, lowers weight, and reduces cardiovascular events causing erectile dysfunction through an unidentified mechanism should be held loosely.

What is missing is a randomized trial with erectile function as a prespecified outcome. Until that exists, the summary is an association of uncertain meaning.

What to do with this

This is not a reason to stop or decline a GLP-1 medication. The cardiovascular and metabolic benefits are established, they are measured in mortality, and erectile function does not outrank them.

It is a reason to raise the subject. If erectile function was already a problem before starting, say so, and ask that it be reviewed rather than assumed to be improving alongside the weight. If it changed after starting, report it as a possible drug effect rather than as an inevitable feature of getting older.

Have testosterone checked if it has not been. Obesity suppresses testosterone, and weight loss typically raises it, so a man whose erections have not improved despite significant weight loss has a question to investigate.

If erections have not improved with the weight

Vascular damage that has already occurred does not reverse with weight loss. Where erectile tissue has lost smooth muscle and gained collagen through years of metabolic disease, it cannot expand fully or compress the draining veins effectively. The erection builds and then fades.

That pattern is a retention problem, and it responds poorly to medication that works on inflow. It is venous leak, and it can be confirmed rather than assumed with a duplex Doppler scan.

An anchored constriction device slows venous outflow and holds position during intercourse, which compensates for the retention failure mechanically. It has no effect on weight, blood sugar, testosterone, or the vascular damage itself, and it requires that some degree of erection can be achieved. It compensates rather than treats. Maximum continuous wear is 30 minutes; remove before sleeping; remove immediately for numbness, coldness, discoloration, or pain — see using a constriction device safely.

Do not stop or change a prescribed medication without speaking to the doctor who prescribed it.

Related reading

• Venous Leak and Erectile Dysfunction Explained
• Penile Duplex Doppler: What the Test Involves
• Vasculogenic ED: Arterial vs Venous Causes
• Diabetes and Erectile Dysfunction
• 8 Treatment Types for ED

References

• Tang H, Lu Y, Zhang B, Zhang D, Asch DA, Chen Y. GLP-1 receptor agonist and risk of erectile dysfunction in men with type 2 diabetes: a target trial emulation. eClinicalMedicine. 2026;94:103857.
• Able C, et al. Prescribing semaglutide for weight loss in non-diabetic, obese patients is associated with an increased risk of erectile dysfunction: a TriNetX database study. International Journal of Impotence Research. 2025;37:315–319.

If you have questions about anything in this article, write to us at hello@xialla.com. We read and answer every message.